sugammadex
- Product NDC
- 70069-893
- 11-digit product format
- 700690893
- Labeler code
- 70069
- Product ID
- 70069-893_6a17af4d-54a4-4366-bb3c-268afd742d0f
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- sugammadex
- Dosage form
- INJECTION, SOLUTION
- Route
- INTRAVENOUS
- Labeler
- Somerset Therapeutics, LLC
- Application
- ANDA215260
- Marketing category
- ANDA
- Marketing start
- 2026-07-28
- Substance
- SUGAMMADEX SODIUM
- Active strength
- 100 mg/mL
- Pharmacologic classes
- gamma-Cyclodextrins [CS]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A215260-001 | SUGAMMADEX SODIUM | SUGAMMADEX SODIUM | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-07-28 | |
| A215260-002 | SUGAMMADEX SODIUM | SUGAMMADEX SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-07-28 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A215260-001 | AP |
| A215260-002 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A215260-001 | SUGAMMADEX SODIUM | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-07-28 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A215260-002 | SUGAMMADEX SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-07-28 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A215260-001 | SUGAMMADEX SODIUM | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-07-28 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A215260-002 | SUGAMMADEX SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | SOLUTION / INTRAVENOUS | AP | 2026-07-28 | caaa826d4ba7… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A215260-001 | AP | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A215260-002 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A215260-001 | AP | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A215260-002 | AP | 1 | caaa826d4ba7… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- sugammadex
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| SUGAMMADEX SODIUM | 100 mg/mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| ERJ6X2MXV7 | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 70c00636-d4ba-4939-802c-9d5a92435c93 | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| sugammadex | SUGAMMADEX | Medical Purchasing Solutions, LLC | 5b14e457-5ea1-3fe2-e063-6294a90aff6f | 2026-09-09 | Warnings, Adverse reactions | 215260 ANDA215260 |
| sugammadex | SUGAMMADEX SODIUM | Solupharm Pharmazeutische Erzeugnisse GmbH | f92c4e53-13d1-46f2-acf8-6730c3cfac69 | 2026-08-20 | Warnings, Adverse reactions | 215260 ANDA215260 |
| sugammadex | SUGAMMADEX | Somerset Therapeutics, LLC | 70c00636-d4ba-4939-802c-9d5a92435c93 | 2026-08-03 | Warnings, Adverse reactions | 215260 ANDA215260 70069-893 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 70069-893-10 | 70069089310 | 10 VIAL, SINGLE-DOSE in 1 CARTON (70069-893-10) / 5 mL in 1 VIAL, SINGLE-DOSE (70069-893-01) | 2026-07-28 | No | No | Current |